Takeda Pharmaceutical Limited (TAK) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Suppliers, else..
 
Takeda Pharmaceutical Company Limited  (NYSE: TAK)
 

Takeda Pharmaceutical Limited Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TAK Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q1 MRQ) 0.06 % 4.83 % 3.99 % 4.2 %
Q / Q Revenue Growth (Q1 MRQ) - -8.49 % -5.34 % -3.92 %
Y / Y Revenue Growth (for 12 months ending Q1 TTM) 0.06 % 7.88 % 5.43 % %
Sequential Revenue Growth (for 12 months ending Q1 TTM) - 0.94 % 0.76 % 1.07 %
Revenue 5 Year Average Growth -0.73 % 7.41 % 8.65 % 10.59 %


TAK's Growth Comparisons in IV. Quarter 2025




Takeda Pharmaceutical Limited's Revenue slowed to the 0.06% year on year, improvement in the fourth quarter 2025 to 29.18 billions, underperforming the 4.83% growth in the Major Pharmaceutical Preparations industry and 3.99% Revenue growth in the Healthcare sector. Comparing the fourth quarter, sales Takeda Pharmaceutical Company Limited was trailing overall market not just Major Pharmaceutical Preparations industry.

Sequentially company's Revenue were unchanged from the third quarter results. . Looking into annual growth, sales grew by -0.73% on average in last five years, while S & P 500's including only Businesses with the fourth quarter 2025 earnings reports, average yearly sales growth is 10.59%.

TAK Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Sales of pharmaceutical products
-
-
Out-licensing and service income
-
-
Total Gastroenterology
-
-
ENTYVIO
-
-
GATTEX REVESTIVE
-
-
TAKECAB VOCINTI
-
-
PANTOLOC CONTROLOC
-
-
DEXILANT
-
-
EOHILIA
-
-
Others
-
-
Total Rare Diseases
-
-
TAKHZYRO
-
-
ADVATE
-
-
ELAPRASE
-
-
REPLAGAL
-
-
ADYNOVATE ADYNOVI
-
-
VPRIV
-
-
LIVTENCITY
-
-
ADZYNMA
-
-
Total PDT
-
-
Immunoglobulin
-
-
Albumin
-
-
Total Oncology
-
-
ADCETRIS
-
-
LEUPLIN ENANTONE
-
-
NINLARO
-
-
ICLUSIG
-
-
FRUZAQLA
-
-
ALUNBRIG
-
-
Total Vaccines
-
-
QDENGA
-
-
Total Neuroscience
-
-
VYVANSE ELVANSE
-
-
TRINTELLIX
-
-
ADDERALL XR
-
-
Total Other
-
-
AZILVA
-
-
FOSRENOL
-
-
Japan
-
-
U S
-
-
Europe and Canada
-
-
Latin America
-
-
China
-
-
Asia excluding Japan China
-
-
Russia CIS
-
-
Other
-
-
Cencora Group Customer risk concentration net sales
-
-
McKesson Group Customer risk concentration net sales
-
-
Total
-
-


Growth Rates of TAK's Income in the fourth quarter 2025


TAK Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q1 MRQ) 49.02 % 172.13 % 98.32 % 2.39 %
Sequential Operating Income Change (Q1 MRQ) - 55.43 % 29.36 % 12.67 %
Y / Y Operating Income Growth (Q1 TTM) 49.02 % 126.07 % 77.41 % 6.79 %
Sequential Operating Income Growth (Q1 TTM) 49.02 % 22.55 % 17.31 % 0.65 %
Operating Income 5 Year Avg. Change 18.76 % 14.39 % 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q1 MRQ) -30.16 % 898.07 % 254.08 % 14.03 %
Sequential Income from Cont. Ops. Change (Q1 MRQ) - - 3992.22 % 0.54 %
Y / Y Income from Cont. Ops. Change (Q1 TTM) -30.16 % 212.02 % 146.7 % 13 %
Sequential Income from Cont. Ops. Change (Q1 TTM) -30.16 % 34.82 % 14.55 % 2.54 %
Income from Cont. Ops. 5 Year Avg. Change -56.51 % -0.55 % 0.17 % -28.52 %

TAK Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q1 MRQ) -30.16 % 887.74 % 257.84 % 13.51 %
Q / Q Net Income Growth (Q1 MRQ) - 14.78 % 19.03 % -0.08 %
Y / Y Net Income Change (Q1 TTM) -30.16 % 62.88 % 57.78 % 11.01 %
Sequential Net Income Change (Q1 TTM) -30.16 % 32.51 % 23.6 % 2.45 %
Net Income 5 Year Avg. Growth 11.07 % 14.55 % 9.21 % 22.96 %

TAK's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q1 MRQ) - 665.83 % 254.08 % 14.03 %
Sequential EPS from Cont. Ops. Change (Q1 MRQ) - - 3992.22 % 0.54 %
Y / Y EPS from Cont. Ops. Change (Q1 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q1 TTM) - - - -23.98 %
EPS from Cont. Ops. 5 Year Avg. Growth 10.91 % -10.79 % 0.17 % -28.52 %



TAK EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q1 MRQ) - 657.91 % 257.84 % -28.52 %
Q / Q EPS Net Growth (Q1 MRQ) - 2.54 % 19.03 % -0.08 %
Y / Y EPS Net Change (for 12 months ending Q1 TTM) - - - 0.14 %
Sequential EPS Net Change (for 12 months ending Q1 TTM) - - - -23.99 %
EPS Net 5 Year Avg. Change 10.54 % 14.55 % 9.21 % 22.96 %



Takeda Pharmaceutical Limited reported bottom-line of $ 0.00 in the fourth quarter, compare to $ 0.62 in the same quarter a year ago. Major Pharmaceutical Preparations industry grew by 657.91%, while Healthcare sector increased by 257.84%, and overall market improved by 13.51%.

Sequentially company's EPS were unchanged from the third quarter results. . Looking into annual growth, income per share grew by 10.54% on average in the last five years, while the S & P 500's including only the businesses with the fourth quarter 2025 financial results, average yearly income per share growth is 22.96%.

TAK Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q1 MRQ) 31.7 % -12.95 % -2.89 % -92.81 %
Sequential Free Cash Flow Change (Q1 MRQ) - -66.41 % -70.2 % -98.71 %
Y / Y Free Cash Flow Change (Q1 TTM) 31.7 % 33.93 % 27.33 % 7.78 %
Sequential Free Cash Flow Change (Q1 TTM) 31.7 % 12.59 % 7.43 % -2.25 %
Free Cash Flow 5 Year Avg. Change -3.48 % 1.86 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q1 MRQ) - 278.38 % - -
Sequential Net Cash Flow Change (Q1 MRQ) - 131.68 % - -
Y / Y Net Cash Flow Change (Q1 TTM) - - -80.31 % -
Sequential Net Cash Flow Change (Q1 TTM) - - -59.61 % -
Net Cash Flow 5 Year Avg. Change - 29.88 % 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q1 MRQ) 6.59 % 16.98 % 6.89 % 18.29 %
Sequential Capital Expenditures Change (Q1 MRQ) - -19.18 % -19.49 % -17.95 %
Y / Y Capital Expenditures Change (Q1 TTM) 6.59 % 14.59 % 7.83 % 39.53 %
Sequential Capital Expenditures Change (Q1 TTM) 6.59 % 10.45 % 4.13 % 5.69 %
Capital Expenditures 5 Year Avg. Change - 8.94 % 9.18 % 14.72 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.